Stake Completed
SV Health Investors stake in AdvanCell
Announced Feb 2025 (approx.)
Advisers
AdvanCell
Target
Not disclosed
SV Health Investors
Acquirer
- Legal adviser
Investor
- Legal adviser
Other advisers
- Legal adviser
- Target
- AdvanCell
- Acquirer
- SV Health Investors
- Structure
- Minority stake
- Amount raised
- US$112m
- Sector
- Biotech and pharmaceuticals
In the league tables
Similar deals
- Invex Therapeutics acquisition of Rekover Therapeutics Oct 2026 · Biotech and pharmaceuticals
- TPG acquisition of Agilex Biolabs Sep 2026 · A$160m · Biotech and pharmaceuticals
- Telix Pharmaceuticals and ITM Isotope Technologies Munich SE merger Sep 2026 · A$3.3bn · Biotech and pharmaceuticals
- Adelaide University acquisition of South Australian Health and Medical Research Institute (SAHMRI) Aug 2026 · Biotech and pharmaceuticals
- Prestige Consumer Healthcare acquisition of LaCorium Health Jul 2026 · Biotech and pharmaceuticals
Sources
- AdvanCell | Proto Axiom Portfolio protoaxiom.com
- 17 February 2025 jws.com.au
- 2 Feb 2025 AdvanCell successfully completes an oversubscribed US$112M Series C financing brandoncapital.vc
- 19 Feb 2025 JWS assists co-lead investors on AdvanCell's US$112m series C financing effort thelawyermag.com